Skip to content
Plavix, Iscover(clopidogrel)
DuoCover, DuoPlavin, Iscover, Plavix (clopidogrel) is a small molecule pharmaceutical. Clopidogrel was first approved as Plavix on 1997-11-17. It has been approved in Europe to treat acute coronary syndrome, atrial fibrillation, myocardial infarction, peripheral vascular diseases, and stroke. It is known to target P2Y purinoceptor 12.
Download report
Favorite
Searched
BMS
Top 200 Pharmaceuticals by Retail Sales
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
cardiovascular diseasesD002318
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Plavix (generic drugs available since 2008-01-14)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Clopidogrel bisulfate
Tradename
Company
Number
Date
Products
PLAVIXSanofiN-020839 RX1997-11-17
2 products, RLD
Labels
FDA
EMA
Brand Name
Status
Last Update
clopidogrelANDA2023-06-12
plavixNew Drug Application2021-03-05
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
B: Blood and blood forming organ drugs
B01: Antithrombotic agents
B01A: Antithrombotic agents
B01AC: Platelet aggregation inhibitors excl. heparin
B01AC04: Clopidogrel
HCPCS
Code
Description
G9531
Patient has documentation of ventricular shunt, brain tumor, multisystem trauma, or is currently taking an antiplatelet medication including: abciximab, anagrelide, cangrelor, cilostazol, clopidogrel, dipyridamole, eptifibatide, prasugrel, ticlopidine, ticagrelor, tirofiban, or vorapaxar
Clinical
Clinical Trials
641 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Coronary artery diseaseD003324I25.1715228822149
Acute coronary syndromeD054058EFO_00056726102242887
Healthy volunteers/patients4114248
Myocardial infarctionD009203EFO_0000612I21151419441
StrokeD020521EFO_0000712I63.9251113432
Percutaneous coronary interventionD06264515811629
Coronary diseaseD0033271218424
Atrial fibrillationD001281EFO_0000275I48.01614122
Ischemic strokeD0000832422485521
Cardiovascular diseasesD002318EFO_0000319I9822311220
Show 69 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Intracranial arteriosclerosisD002537EFO_1000860I67.2133
Congenital heart defectsD006330HP_0001627Q24.9123
Cerebral hemorrhageD002543112
Renal insufficiencyD051437HP_0000083N19112
Heart valve diseasesD006349EFO_0009551I0811
Ventricular outflow obstructionD014694EFO_100144811
Pancreatic neoplasmsD010190EFO_0003860C2511
Middle cerebral artery infarctionD020244EFO_1001045G46.011
ThrombophiliaD019851D68.5911
Coronary artery bypassD001026EFO_000377611
Show 6 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Head and neck neoplasmsD006258112
HivD006678O98.7112
Respiratory insufficiencyD012131HP_0002093J96.911
Embolism and thrombosisD01676911
Viral pneumoniaD011024EFO_0007541J12.911
Cognition disordersD00307211
Hiv infectionsD015658EFO_0000764B2011
Chronic obstructive pulmonary diseaseD029424EFO_0000341J44.911
Critical illnessD01663811
Polycythemia veraD011087D4511
Show 8 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypercholesterolemiaD006937HP_0003124112
Therapeutic equivalencyD01381022
PharmacokineticsD01059922
FastingD005215EFO_000275622
HemostasisD00648722
Hyperlipoproteinemia type vD006954Orphanet_70470E78.311
Major depressive disorderD003865EFO_0003761F2211
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Drug-eluting stentsD05485522
Hip fracturesD006620EFO_0003964S72.0022
Asymptomatic diseasesD05807022
Coronary occlusionD054059I2111
Cerebral amyloid angiopathyD016657EFO_0006790I68.011
Surgical blood lossD01606311
HyperuricemiaD03346111
HemolysisD00646111
EndotoxemiaD01944611
Secondary preventionD05550211
Show 13 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCLOPIDOGREL
INNclopidogrel
Description
Clopidogrel is a thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group, the methylene hydrogen of which is replaced by a methoxycarbonyl group (the S enantiomer). A P2Y12 receptor antagonist, it is used to inhibit blood clots and prevent heart attacks. It has a role as a platelet aggregation inhibitor, an anticoagulant and a P2Y12 receptor antagonist. It is a thienopyridine, a member of monochlorobenzenes and a methyl ester. It is functionally related to a ticlopidine.
Classification
Small molecule
Drug classplatelet aggregation inhibitors, primarily platelet P2Y12 receptor antagonists
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1
Identifiers
PDB
CAS-ID113665-84-2
RxCUI32968
ChEMBL IDCHEMBL1771
ChEBI ID37941
PubChem CID60606
DrugBankDB00758
UNII IDA74586SNO7 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
P2RY12
P2RY12
Organism
Homo sapiens
Gene name
P2RY12
Gene synonyms
HORK3
NCBI Gene ID
Protein name
P2Y purinoceptor 12
Protein synonyms
ADP-glucose receptor, ADPG-R, G-protein coupled receptor SP1999, Gi-coupled ADP receptor HORK3, P2T(AC), P2Y(AC), P2Y(ADP), P2Y(cyc), P2Y12 platelet ADP receptor, purinergic receptor P2RY12, purinergic receptor P2Y, G-protein coupled, 12, putative G-protein coupled receptor, SP1999
Uniprot ID
Mouse ortholog
P2ry12 (70839)
P2Y purinoceptor 12 (Q9CPV9)
Variants
Clinical Variant
Identifier
Target mutation
Effect
Evaluation
Status
VCV000638797CYP2C19, Pro227=drug response2019-06-17P
VCV000638790CYP2C19, LOC110599570, Met1Valdrug response2019-06-17P
VCV000638258CYP2C19, Arg433Trpdrug response2019-06-17P
VCV000638257CYP2C19drug response2019-06-17P
VCV000638256CYP2C19, Arg132Glndrug response2019-06-17P
VCV000638255CYP2C19, Met1Valdrug response2019-06-17P
VCV000638254CYP2C19, Trp120Argdrug response2019-06-17P
VCV000638253CYP2C19, Trp212Terdrug response2019-06-17P
VCV000638251CYP2C19, LOC110599570drug response2019-06-17P
VCV000638207CYP2C19, LOC110599570drug response2019-06-17P
Show 46 more
Financial
Plavix - Bristol Myers Squibb
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Plavix - Sanofi
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 40,523 documents
View more details
Safety
Black-box Warning
Black-box warning for: Clopidogrel, Plavix
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
4,941 adverse events reported
View more details